IPO Journey
Seaport Therapeutics, Inc.
IPO Date: May 1, 2026 · 3 filings tracked
Final Offer Terms
Ticker
SPTX
Exchange
Nasdaq Global Select Market
Offer Price
$18.00
Shares Offered
14,160,000
Estimated Proceeds
$254.9M
Expected Listing
May 04, 2026
Underwriters
Led by Goldman Sachs & Co. LLC, J.P. Morgan
Leerink PartnersCitigroupStifel
Filing Timeline
1
S-1
April 10, 2026
- Proprietary 'Glyph' technology platform improves drug absorption and reduces liver-related side effects.
- Led by a proven management team with a track record of a $14 billion exit at Karuna Therapeutics.
2
S-1/A
April 27, 2026
- Proprietary 'Glyph' platform bypasses the liver for targeted brain drug delivery
- Potential for lower drug dosages and reduced side effects like nausea and sedation
Changes from previous filing
- ▸ Expected offer range: $16.0 – $18.0 per share
- ▸ Shares offered: 11,800,000
- ▸ Estimated proceeds: $188M
424B4
Final Pricing
May 1, 2026
- Proprietary 'Glyph' platform bypasses the liver to improve drug delivery to the brain.
- Leadership team includes co-founders of Karuna Therapeutics, which achieved a $14 billion exit.
Changes from previous filing
- ▸ Exchange: Nasdaq Global Select Market
- ▸ Price range removed
- ▸ Final offer price: $18.0 per share
- ▸ Shares offered: 14,160,000
- ▸ Estimated proceeds: $254M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.